# JCOG0403

Source: https://onco.cc/trials/jcog0403/  
OnCo record `jcog0403` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JCOG0403 gave the first prospective evidence that stereotactic lung radiotherapy works in patients who could have had surgery, not only in those too frail for it, and set the 48 Gy in four fractions schedule used across Japan.

## Summary

JCOG0403 was a two-cohort phase 2 trial of stereotactic body radiotherapy (48 Gy in four fractions) for stage IA non-small-cell lung cancer, enrolling 65 operable and 104 inoperable patients. Three-year overall survival was 76.5 percent in the operable cohort and 59.9 percent in the inoperable one, with acceptable toxicity (Nagata and colleagues, International Journal of Radiation Oncology Biology Physics 2015). It prompted the randomised comparisons of surgery and stereotactic radiotherapy that followed.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-16
- Tags: radiation-wave2
- Phase: 2
- Setting: Stage IA non-small-cell lung cancer, operable and inoperable patients: stereotactic body radiotherapy 48 Gy in four fractions
- Sponsor: Japan Clinical Oncology Group
- Enrolled: 169
- Result: 3-year overall survival 76.5% (operable) and 59.9% (inoperable) after 48 Gy in 4 fractions.

## Sources

- IJROBP 2015: https://doi.org/10.1016/j.ijrobp.2015.07.2278

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)

---
JSON: https://onco.cc/api/v1/entities/jcog0403.json